PAVE 0.28ZWS.TO -0.03VMO.TO 0.53ZAP 0.15CAT 1.97AMZN -2.48GL 0.33DAL -1.96
Stryker Corp. (SYK)

NYSE:SYK

Stryker Corp. (SYK)

339.21
-1.88 (0.55%)
as of Aug 14, 2026, 8:00:00 pm Market Open.
260 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 16, 2026, 12:00 am

This summary was created by AI, based on 8 opinions in the last 12 months.

Stryker Corp. (SYK) is a leading player in the orthopedic medical device sector, holding a significant 70% market share in the U.S. for its robotics platform. The company's revenue is majorly sourced from the U.S., indicating its strong domestic presence and reliance on aging demographics for growth. Despite facing challenges such as a cyber attack and general weakness in the med-tech sector, experts believe that Stryker is poised for recovery and market share regaining, bolstered by a consistent demand for hip and knee replacements. Analysts are optimistic about the company's future growth prospects, with a noted increase in earnings expectations and the attractiveness of current valuations. With a reliable 1% dividend yield that is expected to grow, Stryker remains a favored choice among investors, though some caution against immediate investment due to current market conditions.

consensus icon
Consensus
Positive
valuation icon
Valuation
Fair Value
review icon
Similar
ZBH
BUY

Stryker Corp.(SYK)

Jun 27, 2019
The medical device sector has been a leading group for the last three years and he has been a big proponent. They are interesting because it is secular growth. Demographics support what these companies are doing. They are very defensible because they are not tied to the economic cycle. So long as growth performs well, he likes this group. He owns it through the medical devices ETF.
Photo of David BurrowsDavid Burrows
Owned
Unlock Rating
$202.54

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Stryker Corp.(SYK)

Jun 21, 2019
(A Top Pick Aug 17/18, Up 20%) Hips and knees. Robots doing knee surgery. 3D replacements for hips. Continues to chug along. Growing revenue 6-7%.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$202.72

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Jun 04, 2019

Medical devices in a great demographic growth area. They are developing robotics to assist in surgery. Think of it as a med-tech company. Yield 1.1% (Analysts’ price target is $201.12)

Photo of Zachary Curry Zachary Curry
Owned
Unlock Rating
$186.45

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

May 21, 2019
Medical devices company. Great company. Will continue to grow with the aging population. 73% of the business in the U.S., 23% in Europe and the rest emerging markets. Can grow their business internationally. Very little debt. Great story, great growth and operating margins. (Analysts’ price target is $201.12)
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$185.45

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Stryker Corp.(SYK)

May 03, 2019
(A Top Pick Mar 21/18, Up 17%) Fantastic company in diverse medical devices. Leader in hip and knee replacements. Latest quarter was fantastic.
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$190.71

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Stryker Corp.(SYK)

Apr 22, 2019
Great company, trading cheap in the low-20's. It will do well as its competitors stumble.
Photo of Gordon ReidGordon ReidUnlock Rating
$182.16

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Stryker Corp.(SYK)

Apr 09, 2019
A great company that makes medical devices and does hip replacements. A surgeon that uses their equipment won't suddenly switch to another brand; the doctor will stay with Stryker. A problem is that sometimes the FDA approves medical devices too quickly--though that isn't a problem with Stryker. This is a good long-term hold.
Photo of Paul Harris, CFAPaul Harris, CFA
No
Unlock Rating
$195.97

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Stryker Corp.(SYK)

Mar 21, 2019
The valuation is about a 10-15% premium to the market. It has predictable growth and has done quite well. They have distinguished themselves in the way they can execute. He prefers this one to others in the space. He would be interested at a lower price.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$198.00

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Stryker Corp.(SYK)

Feb 15, 2019
Earnings in last quarter had 6-7% organic growth, 2-3 times better than the competition. Not cheap at 23x earnings. Has differentiated itself from the others in its industry. As long as dividends are growing at a hefty rate, no reason to sell.
Photo of David DriscollDavid DriscollUnlock Rating
$187.40

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Stryker Corp.(SYK)

Feb 13, 2019
A great medical tech company making equipment for knee replacements and spines. SYK spends a lot of time training doctors to use their equipment, which is not interchangeable with other manufacturers, so those doctors will continue to use SKY equipment. Demographics as society ages help SYK. Well-run, and it hit new highs today. This is a great story. Will do well long-term.
Photo of Paul Harris, CFAPaul Harris, CFAUnlock Rating
$185.63

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Stryker Corp.(SYK)

Feb 06, 2019
They do knee and hip replacements. SYK are active in tuck-in acquisitions which is quite accretive. They trade at a decent valuation. A consistent stock performer.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$180.70

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Feb 04, 2019
Has grown its dividend 12% compounded over 5 years. A great international growth story in medical devices. They continue to invest in new technology. They're gaining market share. They're using robots to speed up operations with fewer problems. (Analysts’ price target is $190.40)
Photo of John O'Connell, CFAJohn O'Connell, CFA
Owned
Unlock Rating
$176.29

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Nov 20, 2018
His focus on healthcare equipment. Demographically positive. They make artificial knees and hips, and have introduced robots. Has held in well in market uncertainty. Will be developing more and more technologies. Yield is 1.1%. (Analysts’ price target is $185.27)
Photo of Zachary Curry Zachary Curry
Owned
Unlock Rating
$165.95

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Stryker Corp.(SYK)

Oct 12, 2018

(A Top Pick August 21/17, Up 20%) Hips and knees. Robotic surgery and 3D printers. His fear is that Stryker will buy Globus, and the subsidiary will overtake the parent.

Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$171.04

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Stryker Corp.(SYK)

Sep 12, 2018

This is a great company, he says, with a well-established track record. The price is getting to the point, where you are paying a premium at this level. He would diversify into other holdings as well, ideally through an ETF such as IHI-N

Photo of Cameron HurstCameron Hurst
No
Unlock Rating
$173.29

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 106 to 120 of 174 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

META -5.12$589.85
NVDA -0.14$225.16
ORCL -5.7$150.52
VEQT.TO -0.23$62.79
VBAL.TO -0.17$40.08
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

PAVE 0.28$58.59
ZWS.TO -0.03$22.23
VMO.TO 0.53$96.97
ZAP 0.15$33.15
CAT 1.97$856.57

Popular Articles

Latest Sell Signals

QMAX.TO -0.22$25.53
CDZ.TO -0.01$46.94
VFV.TO -1.06$191.64
HTA.TO -0.14$22.93
ZEB.TO 0.38$78.29

Most Recent Experts

Bill Baruch, Founder, Blue Line Capital

Bill Baruch, Founder, Blue Line Capital

Blue Line Capital

Richard Orrell

Richard Orrell

RN Croft Financial Group

Stan Wong

Stan Wong

Private Wealth Management, ScotiaMcleod

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like